Application of the area under the curve of carboplatin in predicting toxicity and efficacy

Cancer Treatment Reviews

Volumn 24, Issue 6, 1998, Pages 407-414

  De Lemos, Mário L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; MITOMYCIN C; NITROSOUREA;

AREA UNDER THE CURVE; ATOMIC ABSORPTION SPECTROMETRY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; COMPARTMENT MODEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OVARY CANCER; PREDICTION; REVIEW; THROMBOCYTOPENIA; VOMITING;

EID: 0032468855     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(98)90003-2     Document Type: Article

References (50)

1. Hryniuk, WM & Bush, H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J. Clin. Oncol. 1984; 2: 1281-1288.
2. Hryniuk, WM. More is better [editorial]. J. Clin. Oncol. 1988; 6: 1365-1367.
3. De Vita, Jr, VT. Dose-response is alive and well [editorial]. J. Clin. Oncol. 1986; 4: 1157-1159.
4. Reilly, JJ & Workman, P. Normalisation of anti-cancer drug dosage using body weight and surface area: is it worthwhile? Cancer Chemother. Pharmacol. 1993; 32: 411-418.
5. Freireich, EJ, Gehan, EA, Rail, DP, Schmidt, LH & Skipper, HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer. Chemother. Rep. 1966; 50: 219-244.
6. Grochow, LB, Baraldi, C & Noe, D. Is dose normalization to weight or body surface area useful in adults? J. Natl. Cancer Inst. 1990; 82: 323-325.
7. Intravenous dose. In: Rowland, M & Tozer, TN. Clinical Pharmacokinetic: Concepts and Applications, second edition. London: Lea & Febiger, 1989; p17-32.
8. Mamelok, RD. Drug discovery and development. In: Melmon, K.L., Morrelli, H.F., Hoffman, B.B. & Nierenberg, D.W. eds, Clinical Pharmacology: Basic Principles in Therapeutics, third edition. New York: McGraw-Hill, 1992; p911-921.
9. Goldsmith, RF, Slavik, M & Carter, SK. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Research 1975; 43: 1354-1364.
10. Collins, JM, Zaharko, DS, Dedrick, RL & Chabner, BA. Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat. Rep. 1986; 70: 73-80.
11. Harrap, KR. Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev. 1985; 12: 21-33.
12. Alberts, DS, Green, S, Hannigan, EV. et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages 3 and 4 ovarian cancer. J. Clin. Oncol. 1992; 10: 706-717.
13. Calvert, AH, Harland, SJ, Newell, DR. et al. Early clinical studies with cis-diammine-1, 1-cyclobutane dicarboxylate platinum II. Cancer Chemother. Pharmacol. 1982; 9: 140-147.
14. Curt, GA, Grygiel, JJ, Corden, BJ et al. A phase I and pharmacokinetic study of diamminecyclobutanedicarboxylatoplatinum (NSC 241240). Cancer Res. 1983; 43: 4470-4473.
15. Evans, BD, Raju, KS, Calvert, AH, Harland, SJ & Wiltshaw, E. Phase II study of JM8, a new platinum analog in ovarian cancer. Cancer Treat. Rep. 1983; 67: 997-1000.
16. Wiltshaw, E. Ovarian trials at the Royal Marsden. Cancer Treat. Rev. 1985; 12(Suppl A): 67-71.
17. van der Vijgh, WJF. Clinical pharmacokinetics of carboplatin. Clin. Pharmacokinet. 1991; 21: 242-261.
18. Eastman, A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol. Ther. 1987; 34: 155-166.
19. Laurent, G, Erickson, LC, Sharkey, NA & Kohnt, KW. DNA cross-linking and cytotoxicity induced by cis-diamminedichloroplatinum(II) in human normal and tumor cell lines. Cancer Res. 1981; 41: 3347-51.
20. Pinto, AL & Lippard, SJ. Binding of the antitumor drug cisdiamminedichloro platinum(II) (Cisplatin) to DNA. Biochim. Biophys. Acta 1985; 780: 167-180.
21. Roberts, JJ & Friedlos, F. Quantitative estimation of Cisplatin-induced DNA interstrand cross-links and their repair in mammalian cells: relationship to toxicity. Pharmacol. Ther. 1987; 34: 215-246.
22. Smeyers-Verbeke, J, Detaevernier, MR, Denis, L & Massart, DL. The determination of platinum in biological fluid by means of graphite furnace atomic absorption spectrometry. Clin. Chim. Acta 1981; 113: 329-333.
23. Vermerken, JB, van der Vijgh, WJF, Klein, I. et al. Pharmacokinetics of free and total platinum species after rapid and prolonged infusion of cisplatin. Clin. Pharmacol. Ther. 1986; 39: 136-144.
24. Hopfer, SM, Ziebka, L, Sunderman, FW, Sporn, JR & Greenberg, BG. Direct analysis of platinum in plasma and urine by electrothermal atomic absorption spectrophotometry. Ann. Clin. Lab. Sci. 1989; 19: 389-396.
25. Nygren, O, Vaughan, GT, Florence, TM et al. Determination of platinum in blood by adsorptive voltammetry. Anal. Chem. 1990; 62: 1637-1640.
26. Harland, SJ, Newell, DR, Siddik, ZH et al. Pharmacokinetics of cis-diammine-1, 1-cyclobutanedicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984; 44: 1693-1697.
27. Reece, PA, Bishop, JF, Olver, IN, Stafford, I, Hillcoat, BL & Morstyn, G. Pharmacokinetics of unchanged carboplatin (CBDCA) in patients with small cell lung carcinoma. Cancer Chemother. Pharmacol. 1987; 19: 326-330.
28. Gaver, RC & Deeb, G. High-performance liquid Chromatographic procedures for the analysis of carboplatin in human plasma and urine. Cancer Chemother. Pharmacol. 1986; 16: 201-206.
29. Elferink, F, van der Vijgh, WJF, ten Bokkel Huinink, WW. et al. Pharmacokinetics of ethylenediamminemalotoplatinum(II) (JM-40) during phase I trials. Br. J. Cancer 1986; 56: 479-483.
30. Calvert, AH, Newell, DR, Gumbrell, LA. et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 1989; 7: 1748-1756.
31. Egorin, MJ, Van Echo, DA, Tipping, SL. et al Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedicarboxylato) platinum in patients with impaired renal function. Cancer Res 1984; 44: 5432-5438.
32. 51Cr-EDTA. J. Clin. Sci. 1969; 37: 169-190.
33. Newell, DR, Pearson, ADJ, Balmanno, K. et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J. Clin. Oncol. 1993; 11: 2314-2323.
34. Cockcroft, DW & Gault, MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
35. Chatelut, E, Canal, P, Brunner, V. et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J. Natl. Cancer Inst. 1995; 87: 573-580.
36. van Warmerdam, LJ, Rodenhuis, S, ten Bokkel Huinink, WW, Maes, RAA & Beijnen, JH. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother. Pharmacol. 1996; 37: 266-270.
37. Egorin, MJ, Van Echo, DA, Olman, EA, Whitacre, MY, Forrest, A & Aisner, J. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res. 1985; 45: 6502-6506.
38. O'Brien, MER, Talbot, DC & Smith, IE. Carboplatin in the treatment of advanced breast cancer: a phase II study using a mathematically guided dose schedule. J. Clin. Oncol. 1993; 11: 2112-2117.
39. Reed, E, Janik, J, Bookman, MA. et al. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. J. Clin. Oncol. 1993; 11: 2118-2126.
40. Lind, MJ, Ghazal-Aswad, S, Gumbrell, L. et al. Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer. J. Clin. Oncol. 1996; 14: 800-805.
41. Newell, DR, Siddik, ZH, Gumbrell, LA. et al. Plasma free platinum pharmacokinetics in patients treated with high dose car-boplatin. Eur J Cancer Clin. Oncol. 1987; 23: 1399-1405.
42. Calvert, AH. Dose optimisation of carboplatin in adults. Anticancer Res. 1994; 14: 2273-2278.
43. Horwich, A, Dearnaley, DP, Nicholls, J. et al. Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular non-seminomatous germ cell tumours. J. Clin. Oncol 1991; 9: 62-69.
44. Childs, WJ, Nicholls, EJ & Horwich, A. The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann Oncol 1992; 3: 291-296.
45. Jodrell, DI, Egorin, MJ, Canetta, RM. et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J. Clin. Oncol. 1992; 10: 520-528.
46. Wagner, JG. Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J. Theoret. Biol. 1968; 20: 173-201.
47. Gore, M, Mainwaring, P, A'Hern, R et al. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. J. Clin. Oncol. 1998; 16: 2426-2434.
48. Reyno, LM, Egorin, MJ, Canetta, RM et al. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J. Clin. Oncol. 1993; 11: 1156-1164.
49. Egorin, MJ, Reyno, LM, Canetta, EM et al. Modeling toxicity and response in carboplatin-based combination chemotherapy. J. Clin. Oncol. 1994; 21: 7-19.
50. Jakobsen, A, Bertelsen, K, Andersen, JE, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish ovarian cancer group study. J. Clin. Oncol. 1997; 15: 193-198.